Literature DB >> 19378750

Calculation of the biological effective dose for piecewise defined dose-rate fits.

Robert F Hobbs1, George Sgouros.   

Abstract

An algorithmic solution to the biological effective dose (BED) calculation from the Lea-Catcheside formula for a piecewise defined function is presented. Data from patients treated for metastatic thyroid cancer were used to illustrate the solution. The Lea-Catcheside formula for the G-factor of the BED is integrated numerically using a large number of small trapezoidal fits to each integral. The algorithmically calculated BED is compatible with an analytic calculation for a similarly valued exponentially fitted dose-rate plot and is the only resolution for piecewise defined dose-rate functions.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19378750      PMCID： PMC2736747          DOI： 10.1118/1.3070587

Source DB:  PubMed          Journal:  Med Phys        ISSN： 0094-2405            Impact factor:   4.071


  7 in total

1.  Application of the linear-quadratic model with incomplete repair to radionuclide directed therapy.

Authors:  W T Millar
Journal:  Br J Radiol       Date:  1991-03       Impact factor: 3.039

2.  The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships.

Authors:  D J Brenner; L R Hlatky; P J Hahnfeldt; Y Huang; R K Sachs
Journal:  Radiat Res       Date:  1998-07       Impact factor: 2.841

3.  Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.

Authors:  Raffaella Barone; Françoise Borson-Chazot; Roelf Valkema; Stéphan Walrand; Franck Chauvin; Lida Gogou; Larry K Kvols; Eric P Krenning; François Jamar; Stanislas Pauwels
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

4.  The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy.

Authors:  R G Dale
Journal:  Br J Radiol       Date:  1985-06       Impact factor: 3.039

5.  Application of the linear-quadratic model to radioimmunotherapy: further support for the advantage of longer-lived radionuclides.

Authors:  R W Howell; S M Goddu; D V Rao
Journal:  J Nucl Med       Date:  1994-11       Impact factor: 10.057

6.  Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry.

Authors:  Sébastien Baechler; Robert F Hobbs; Andrew R Prideaux; Richard L Wahl; George Sgouros
Journal:  Med Phys       Date:  2008-03       Impact factor: 4.071

7.  Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry.

Authors:  Andrew R Prideaux; Hong Song; Robert F Hobbs; Bin He; Eric C Frey; Paul W Ladenson; Richard L Wahl; George Sgouros
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057
  7 in total
  14 in total

1.  Redefining relative biological effectiveness in the context of the EQDX formalism: implications for alpha-particle emitter therapy.

Authors:  Robert F Hobbs; Roger W Howell; Hong Song; Sébastien Baechler; George Sgouros
Journal:  Radiat Res       Date:  2014-01       Impact factor: 2.841

Review 2.  Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer.

Authors:  George Sgouros; Robert F Hobbs; Francis B Atkins; Douglas Van Nostrand; Paul W Ladenson; Richard L Wahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

3.  Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy.

Authors:  Robert F Hobbs; Sébastien Baechler; Richard L Wahl; Bin He; Hong Song; Caroline E Esaias; Eric C Frey; Heather Jacene; George Sgouros
Journal:  J Nucl Med       Date:  2010-02-11       Impact factor: 10.057

4.  Cellular Response to Exponentially Increasing and Decreasing Dose Rates: Implications for Treatment Planning in Targeted Radionuclide Therapy.

Authors:  Jay H Solanki; Thomas Tritt; Jordan B Pasternack; Julia J Kim; Calvin N Leung; Jason D Domogauer; Nicholas W Colangelo; Venkat R Narra; Roger W Howell
Journal:  Radiat Res       Date:  2017-05-25       Impact factor: 2.841

5.  The biological effectiveness of targeted radionuclide therapy based on a whole-body pharmacokinetic model.

Authors:  Joseph J Grudzinski; Wolfgang Tomé; Jamey P Weichert; Robert Jeraj
Journal:  Phys Med Biol       Date:  2010-09-08       Impact factor: 3.609

6.  A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy.

Authors:  Robert F Hobbs; Todd McNutt; Sébastien Baechler; Bin He; Caroline E Esaias; Eric C Frey; David M Loeb; Richard L Wahl; Ori Shokek; George Sgouros
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-13       Impact factor: 7.038

7.  Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET.

Authors:  R F Hobbs; W Jentzen; A Bockisch; G Sgouros
Journal:  Q J Nucl Med Mol Imaging       Date:  2013-03       Impact factor: 2.346

8.  Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma.

Authors:  Robert F Hobbs; Richard L Wahl; Eric C Frey; Yvette Kasamon; Hong Song; Peng Huang; Richard J Jones; George Sgouros
Journal:  J Nucl Med       Date:  2013-08-05       Impact factor: 10.057

9.  A theoretical dose-escalation study based on biological effective dose in radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin).

Authors:  Massimiliano Pacilio; Margherita Betti; Francesco Cicone; Carolina Del Mastro; Livia Montani; Laura Chiacchiararelli; Alessia Monaco; Enrico Santini; Francesco Scopinaro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

10.  Development and Validation of RAPID: A Patient-Specific Monte Carlo Three-Dimensional Internal Dosimetry Platform.

Authors:  Abigail E Besemer; You Ming Yang; Joseph J Grudzinski; Lance T Hall; Bryan P Bednarz
Journal:  Cancer Biother Radiopharm       Date:  2018-04-25       Impact factor: 3.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.